An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan.

doi:10.1007/s12072-023-10609-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan.

Hepatology international - 1 Apr 2024

Yu Ming-Lung, Tai Chi-Ming, Mo Lein-Ray, Kuo Hsing-Tao, Huang Chung-Feng, Tseng Kuo-Chih, Lo Ching-Chu, Bair Ming-Jong, Wang Szu-Jen, Huang Jee-Fu, Yeh Ming-Lun, Chen Chun-Ting, Tsai Ming-Chang, Huang Chien-Wei, Lee Pei-Lun, Yang Tzeng-Hue, Huang Yi-Hsiang, Chong Lee-Won, Chen Chien-Lin, Yang Chi-Chieh, Hung Chao-Hung, Yang Sheng-Shun, Cheng Pin-Nan, Hsieh Tsai-Yuan, Hu Jui-Ting, Wu Wen-Chih, Cheng Chien-Yu, Chen Guei-Ying, Zhou Guo-Xiong, Tsai Wei-Lun, Kao Chien-Neng, Lin Chih-Lang, Wang Chia-Chi, Lin Ta-Ya, Lin Chih-Lin, Su Wei-Wen, Lee Tzong-Hsi, Chang Te-Sheng, Liu Chun-Jen, Dai Chia-Yen, Chen Chi-Yi, Kao Jia-Horng, Lin Han-Chieh, Chuang Wan-Long, Peng Cheng-Yuan

Abstract excerpt

BACKGROUND: Both European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (AASLD-IDSA) guidelines recommend simplified hepatitis C virus (HCV) treatment with pan-genotypic sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for eligible patients. This observational study used real-world data to assess these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aminoisobutyric Acids

Share to Benzopyrans

Share to Bilirubin

Share to Cyclopropanes

Share to Heterocyclic Compounds, 4 or More Rings

Share to Lactams, Macrocyclic

Share to Quinoxalines

Share to Sofosbuvir

Source

Open in PubMed Open full text

Identifiers

PMID: 38246899
DOI: 10.1007/s12072-023-10609-7
PMCID: PMC11014878

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan.PMID 38246899Read ↗

Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry.Semantic proximity Read ↗

Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan.Semantic proximity Read ↗

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts.Semantic proximity Read ↗

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.Semantic proximity Read ↗

Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection in TaiwanSemantic proximity Read ↗

Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update.Semantic proximity Read ↗

Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.Semantic proximity Read ↗

Efficacy and safety of glecaprevir/pibrentasvir treatment in Koreans with chronic hepatitis C: A retrospective study.Semantic proximity Read ↗

Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study.Semantic proximity Read ↗

Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.Semantic proximity Read ↗

Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.